We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
Read MoreHide Full Article
Key Takeaways
Keytruda accounts for nearly 50% of MRK's pharma revenues, driving growth across cancer indications globally.
Early-stage lung cancer and metastatic uptake are fueling strong sales momentum for Keytruda.
Heavy reliance on Keytruda poses risks as the 2028 loss of exclusivity draws closer.
Merck’s (MRK - Free Report) primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts for almost 50% of the company’s pharmaceutical sales and is a key driver of Merck’s top-line growth.
As Merck prepares to report second-quarter results on July 29, investors will look out for the sales performance of Keytruda. Sales of the drug are likely to have been driven by underlying and rapid uptake across earlier-stage cancers and metastatic indications globally. The Zacks Consensus Estimate for Keytruda’s sales in the second quarter is $7.90 billion, while our estimate is $7.87 billion.
In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of wholesaler purchases. This negative impact is expected to have reversed this time around.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer. Our model estimates for Keytruda sales suggest a CAGR of 5.4% over the next three years.
Though Merck is riding on the success of Keytruda, the company’s heavy dependence on the drug for growth remains a concern. Moreover, Keytruda is set to face loss of exclusivity (LOE) in 2028. Also, competitive pressure might increase for Keytruda in the near future. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Competition From Other PD-L1 Inhibitors
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year.
AZN’s Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 17.9% compared with the industry’s decrease of 2.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.79 forward earnings, lower than 14.60 for the industry and its 5-year mean of 12.81.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.93 per share to $8.85, while the same for 2026 has decreased from $9.74 to $9.63 over the past 60 days.
Image: Bigstock
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
Key Takeaways
Merck’s (MRK - Free Report) primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts for almost 50% of the company’s pharmaceutical sales and is a key driver of Merck’s top-line growth.
As Merck prepares to report second-quarter results on July 29, investors will look out for the sales performance of Keytruda. Sales of the drug are likely to have been driven by underlying and rapid uptake across earlier-stage cancers and metastatic indications globally. The Zacks Consensus Estimate for Keytruda’s sales in the second quarter is $7.90 billion, while our estimate is $7.87 billion.
In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of wholesaler purchases. This negative impact is expected to have reversed this time around.
Keytruda’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. The company expects continued growth from Keytruda, particularly in early lung cancer. Our model estimates for Keytruda sales suggest a CAGR of 5.4% over the next three years.
Though Merck is riding on the success of Keytruda, the company’s heavy dependence on the drug for growth remains a concern. Moreover, Keytruda is set to face loss of exclusivity (LOE) in 2028. Also, competitive pressure might increase for Keytruda in the near future. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Competition From Other PD-L1 Inhibitors
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year.
AZN’s Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 17.9% compared with the industry’s decrease of 2.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.79 forward earnings, lower than 14.60 for the industry and its 5-year mean of 12.81.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.93 per share to $8.85, while the same for 2026 has decreased from $9.74 to $9.63 over the past 60 days.
Image Source: Zacks Investment Research
Merck currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.